Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

In this article:

Cranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient's own T cells to fight cancer.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • WBB Securities, an investment bank specializing in biotechnology, medical devices and life sciences, successfully organized a webinar focusing on the potential of Chimeric Antigen Receptor T-Cells (CAR-T) therapy in the future of cancer treatment.

  • The webinar, organized by CEO Steve Brozak, DMH featured distinguished speakers and experts in the field of CAR-T Cell therapy who provided insights into the science behind the therapy, its clinical applications, and potential market growth.

  • The positive response to the event underscores WBB Securities' role in connecting investors with key developments in the healthcare industry and a growing interest in CAR-T Cell therapy among the investor community.

Click image above to view full announcement.


WBB Securities

The WBB Research Institute is a research organization, founded by WBB Securities. The Institute focuses on emerging critical issues in healthcare that threaten to have profound impact. WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused on the life sciences. WBB Securities is registered with the SEC as a broker-dealer, a FINRA member firm, and a Registered Investment Advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.

Contacts:

Henry Bassman
9085229212
hbassman@wbbsec.com

Source: WBB Securities

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/177588

Advertisement